Impact Factor 3.633 | CiteScore 3.73
More on impact ›

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Aging Neurosci. | doi: 10.3389/fnagi.2019.00244

Emerging alternative proteinases in APP metabolism and Alzheimer’s disease pathogenesis: a focus on MT1-MMP and MT5-MMP

  • 1UMR7051 Institut de Neurophysiopathologie, France

Processing of amyloid beta precursor protein (APP) into amyloid-beta peptide (A) by -secretase and -secretase complex is at the heart of the pathogenesis of Alzheimer’s disease (AD). Targeting this proteolytic pathway effectively reduces/prevents pathology and cognitive decline in preclinical experimental models of the disease, but therapeutic strategies based on secretase activity modifying drugs have so far failed in clinical trials. Although this may raise some doubts on the relevance of - and -secretases as targets, new APP-cleaving enzymes, including meprin-, legumain (-secretase), rhomboid-like protein-4 (RHBDL4), caspases and membrane-type matrix metalloproteinases (MT-MMPs/-secretases) have confirmed that APP processing remains a solid mechanism in AD pathophysiology. This review will discuss recent findings on the roles of all these proteinases in the nervous system, and in particular on the roles of MT-MMPs, which are at the crossroads of pathological events involving not only amyloidogenesis, but also inflammation and synaptic dysfunctions. Assessing the potential of these emerging proteinases in the Alzheimer's field opens up new research prospects to improve our knowledge of fundamental mechanisms of the disease and help us establish new therapeutic strategies.

Keywords: amyloid precursor protein, matrix metalloproteinase, secretase, proteinase inhibitor, Meprin, Legumain, rhomboid-like protein-4, caspase, Brain, Neurodegerative disease

Received: 30 Jun 2019; Accepted: 20 Aug 2019.

Copyright: © 2019 García-González, Pilat, Baranger and Rivera. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Dr. Kévin Baranger, UMR7051 Institut de Neurophysiopathologie, Marseille, France, kevin.baranger@univ-amu.fr
Dr. Santiago Rivera, UMR7051 Institut de Neurophysiopathologie, Marseille, France, santiago.rivera@univ-amu.fr